Licenses antibody drug candidates to pharmaceutical and biotechnology companies, and discovers and develops antibody medicines for patients with unmet medical needs.
10-K for FY2025, filed Feb 24, 2026AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications…View ↗
As part of our historical business, partners seeking a competitive advantage would approach us with ideas for new antibody drugs and…View ↗
We have extensive experience partnering with leading pharmaceutical companies, emerging biotechnology companies, and non-profit and…View ↗
Partners pay royalties tied to sales of licensed drugs, fixed fees for access and discovery research, and milestone payments when specified development or commercial events occur. Research fees are payable at the beginning and end of work phases.
10-K for FY2025, filed Feb 24, 2026F-9 the customer of licensed drugs, and in some cases, (vi) early termination penalties, and (vii) reimbursements for costs incurred to…View ↗
The transaction price generally includes fixed fees due at contract inception as well as fixed fees payable at the beginning and end of…View ↗
As part of our historical business, partners seeking a competitive advantage would approach us with ideas for new antibody drugs and…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$75.1M
10-K for FY2025, filed Feb 24, 2026
$75.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Research fees
Recurring
10-K for FY2025, filed Feb 24, 2026 |
36%
FY2022: 8.4%
|
Research fees, FY2025
$27.2M Sources
|
Recurring |
|
Milestone payments
Sold outright
|
1.3%
FY2022: 0.2%
|
Milestone payments, FY2025
$1M Sources
|
Sold outright |
|
Licensing and royalty revenue
Licensed
10-K for FY2025, filed Feb 24, 2026 |
62%
FY2022: 0.1%
|
Licensing and royalty revenue, FY2025
$46.9M Sources
|
Licensed |
Pharmaceutical and biotechnology companies, as well as nonprofit and government organizations, partner with AbCellera on antibody-discovery programs. AbCellera also seeks partners to develop and commercialize its own pipeline medicines.
10-K for FY2025, filed Feb 24, 2026
No. It lost $146.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$40.8MView ↗
8-K, filed Jul 29, 2026
On July 29, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a collaboration with Vertex Pharmaceuticals…View ↗
8-K, filed Jun 17, 2026
On June 17, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a preclinical research collaboration, option…View ↗
Shrinking. Revenue fell 80% in 4 years, from $375.2M in FY2021 to $75.1M in FY2025, about 33% a year.
From partnerships to an internal pipeline
The earlier report centered on applying its antibody discovery platform to partner programs and building royalty stakes. The latest report centers on developing AbCellera-owned drug candidates, with programs in clinical trials.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 24, 2026
Loading...